ImmuCell Reports Strong Q1 2026 Results with 28.4% Revenue Growth and Increased Profitability
ICCC sits 83% above its 52-week low of $4.52.
Summary
ImmuCell Corporation announced robust first-quarter 2026 financial results, reporting a 28.4% increase in product sales to $10.4 million and a significant rise in net income and cash flow.
Key Events · Earnings and Guidance · ICCC
-
Strong Q1 2026 Financial Results
Product sales increased 28.4% to $10.4 million for the quarter ended March 31, 2026, compared to the same period in 2025.
-
Improved Profitability
Net income rose to $1.9 million, or $0.21 per basic share, from $1.4 million, or $0.16 per basic share, year-over-year. Gross margin expanded to 45.0% from 41.6%.
-
Significant Cash Flow Generation
The company generated $3.4 million in free cash flow during Q1 2026, increasing cash and cash equivalents to $6.8 million as of March 31, 2026, from $3.8 million at year-end 2025.
-
Operational Improvements & Expansion Plans
Average manufacturing output increased to over 450,000 units per month. The company plans to deploy a recent $2 million settlement payment towards a significant First Defense® capacity expansion.
Analysis · ICCC · Life Sciences
The company delivered strong Q1 2026 performance, driven by substantial revenue growth, improved gross margins, and increased net income. The generation of significant free cash flow has bolstered its cash position, providing capital for planned capacity expansion, which is critical for meeting growing demand and sustaining market share gains.
At the time of this filing, ICCC was trading at $8.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $4.52 to $9.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.